1 SESSION 7: PRECLINICAL & TOXICOLOGY MODELS IN IMMUNO-ONCOLOGY Challenges in the evaluation of preclinical toxicology in immuno-oncology Belén Gracia Moneva Spanish Medicines and Healthcare Products Agency AEMPS Innsbruck, 21 October 2016
2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to the Spanish Medicines and Healthcare Products Agency (AEMPS) or European Medicines Agency (EMA)
3 Immunological treatment options -Monoclonal antibodies -Proteins of immunological control -Adoptive cellular therapy -Cytokines -Others
5 Targets PD-1 Nivolumab- monoclonal antibody anti- PD-1 metastatic melanoma, non-small cell lung cancer and advanced renal carcinoma Pembrolizumab monoclonal antibodyanti-pd-1 metastatic melanoma, lung cancer
6 Targets Signaling lymphocytic activation molecule F7 (SLAMF7) Anti-SLAMF7 antibody, elotuzumab, for multiple myeloma (MM). Receptor present on immune cells, including NK cells. It is also expressed on MM cells. Killer Cell Immunoglobulin Like Receptor (KIR) Anti-KIR antibodies prevents a tolerogenic interaction and augments NK-cell spontaneous cytotoxicity Tumor necrosis super family receptors (TNFRSF) Agonistic antibodies of TNFRSF family of costimulatory receptors (CD134, CD137, etc) predominantly expressed by T-lymphocytes, NKTcells, NK cells and neutrophils that generates an anti-tumor response
7 Targets T-lymphocyte associated antigen-4 (CTLA-4) Anti-CTLA-4-Ipilimumab- anticytotoxic T-lymphocyte associated antigen-4 (CTLA-4) mab approved for the treatment of metastatic melanoma
8 NON-CLINICAL SAFETY ASSESSMENT Guideline S9 on Non-clinical evaluation for anticancer pharmaceuticals in man (EMA/CHMP/ICH/646107/2008) & Q/A doc EMA/CHMP/ICH/453684/2016 This guideline aims to facilitate and accelerate the development of anticancer pharmaceuticals and to protect patients from unnecessary adverse effects, while avoiding unnecessary use of animals, in accordance with the 3R principles (reduce/refine/replace), and other resources.
9 But also, Guideline S6 (R1) on Preclinical safety evaluation of biotechnology-derived pharmaceuticals (EMA/CHMP/ICH/731268/1998) intended to provide general principles for designing scientifically acceptable preclinical safety evaluation programs. 1) to identify an initial safe dose and subsequent dose escalation schemes in humans; 2) to identify potential target organs for toxicity and for the study of whether such toxicity is reversible; and 3) to identify safety parameters for clinical monitoring.
10 Monoclonal antibodies- the immunological properties of the antibody should be described in detail (antigenic specificity, toxicity towards human tissues distinct from the intended target ). Induction of antibody formation in animals is not predictive of a potential for antibody formation in humans. Use of relevant species in safety evaluation programs
11 And, Non-Clinical Safety Studies For The Conduct Of Human Clinical Trials For Pharmaceuticals (ICH M3[R2]) International standards for, and promote harmonisation of, the nonclinical safety studies recommended to support human clinical trials of a given scope and duration as well as marketing authorization for phcals. This guidance should facilitate the timely conduct of clinical trials, reduce the use of animals in accordance with the 3R (reduce/refine/replace) principles and reduce the use of other drug development resources. For biotech products, nc safety package in accordance with ICH S6, M3 only provides guidance with regard to timing of nc studies relative to clinical development.
12 And, Strategies to identify and mitigate risks for first-inhuman clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07) This document addresses non-clinical issues for consideration prior to the first administration of an investigational medicinal product in humans.
13 Others, CHMP/SWP/169215/05 Aug 2008 Need for Non- Clinical Testing in Juvenile Animals on Human Pharmaceuticals for Paediatric Indications Medicinal products under development for specific paediatric indications or in life-threatening or serious diseases without current effective therapies warrant a case-by-case approach. In some cases, some studies may then be adapted, deferred or omitted ICH S10-Photosafety evaluation of pharmaceuticals- Concept paper Jan 2008
14 Guideline S9 on non-clinical evaluation for anticancer pharmaceuticals in man (EMA/CHMP/ICH/646107/2008) 1) Identify the pharmacologic properties of a pharmaceutical 2) Establish a safe initial dose level for the first human exposure and, 3) understand the toxicological profile of a pharmaceutical (identification of target organs, exposure-response relationship, and reversibility). Acceptable safety in humans
15 1) Identify the pharmacologic properties of a pharmaceutical and safety pharmacology Assessment of the pharmaceutical s effect on vital organ functions including cardiovascular, respiratory and central nervous systems available before the initiation of clinical studies. Could be included in general toxicology studies. In the absence of a specific risk, such studies will not be called for to support clinical trials or for marketing.
16 2) Dose selection- LDT and MTD (CLASSIC) The recommended human starting dose is determined by considering all available nonclinical toxicology and pharmacology data. Two approaches: -1 HNSTD-highest non-severely toxic dose from 1-month repeat-dose toxicity study in animal species.--- 1/6 HNSTD---FIH STD10-1/10 the severely toxic dose in 10% animals (STD10) small molecules NOAEL not essential -2 Pharmacology data---percentage of tumour regression plateau mg/kg, Cmax and AUC. Biopharmaceuticals with immune agonistic properties-minimally anticipated biologic effect level (MABEL) should be considered No MAJOR CONCERN IN CALCULATION SAFE STARTING DOSE
17 Dose levels in these clinical studies often are close to or at the adverse effect dose levels Type, timing and flexibility called for in the design of nonclinical studies of anticancer pharmaceuticals can differ from those elements in nonclinical studies for other pharmaceuticals.
18 3) Understand the toxicological profile of a pharmaceutical (identification of target organs, exposure-response relationship, and reversibility). Primary objective of a Phase I clinical trial in patients with advanced cancer is to assess the safety: MTD and DLT. Duration of non-clin studies: 28 days (Phase I,II), 3 months (Phase III) In case of biopharmaceuticals, ---S6 Assessment of the potential to recover from toxicity should be provided to understand the reversibility/irreversibility (1sp) Relevant animal species Immunotoxicological evaluation-immunostimulation, supression, autoimmunity
19 In general, the non-clinical data to support Phase I and the clinical Phase I data would normally be sufficient for moving to Phase II and into a second or first line therapy in patients with advanced cancer.
20 SESSION 7: Other non-clinical data: -Pharmacokinetics in the animal species used for non-clin studies -Reproduction toxicology Embryofetal toxicity studies of anticancer pharmaceuticals should be available when the marketing application is submitted but not essential to support clinical trials in advanced cancer or when are genotoxic or known to cause developmental toxicity. Effects on embryogenesis --Efforts to prevent pregnancy during treatment. Fertility and early embryonic development and pre and postnatal toxicology studies are not warranted in case patients with advanced cancer.
21 -Genotoxicity Not essential for clinical trials in advanced cancer -Carcinogenicity Not essential for clinical trials and marketing in advanced cancer. -Photosafety Phase I (photochemical properties)-photosafety protective measures in CT -Immunotoxicity Specific studies
22 LIMITATIONS -In species-specific cross-reactivity: Lack of relevant animal species in which to conduct toxicological studies- toxicity not predictive for human situation. Non recognition of proteins from other different species than human. The nonclinical safety package consists primarily of in vitro safety and in vivo biological activity assessments. Valuable for nontarget effects. Surrogate animal model -Immunogenicity: ADAs not predictive for human situation -Immune-related adverse events (iraes): Proliferation or cytokine release novel exploratory in vitro cellular proliferation and cytokine release assays. Predictive models?
23 Combination therapies -Well-studied individually in toxicology evaluations. -Rationale for the combination -In general, toxicology studies investigating the safety of combinations of pharm in advanced cancer are not warranted but, -if at least one of these compound is in early stage development (human toxicity profile has not been characterised) a pharmacology study to support the rationale for the combination should be provided that evidence an increased activity in the absence of a substantial increase in toxicity on the basis of limited safety endpoints (mortality, clinical signs, weight gain).
24 Non-clinical studies to support CT in pediatric population Juvenile animals are not usually conducted in order to support inclusion of pediatric populations for the treatment of cancer Only when human safety data and previous animal studies are considered insufficient for safety evaluation in the intended pediatric age group.
25 Ipilimumab -In vitro, ipilimumab binds to human CTLA-4 with high affinity. Ipilimumab did not show cross-reactivity with or binding to CTLA-4 from rats, mice or rabbits, but showed specific binding to cynomolgus monkey recombinant CTLA-4 and activated T-cells. Pharmacological activity only in primates -Safety pharmacology programme (CVS, NS, RS) : in pivotal toxicity studies in monkeys for up to 6 months. No major findings involving safety pharmacology endpoints
26 Ipilimumab -Toxicology: The cynomolgus monkey was selected as the toxicology species in single and repeat dose studies for up to six months because ipilimumab binds specifically to macaque CTLA-4, but not to homologous CTLA-4 in other traditional toxicology species and has pharmacologic activity only in primates. Well tolerated with different immune-related adverse events (iraes) of low incidence linked with the intended pharmacologic basis of CTLA-4 blockade Immunotoxicity assessed in repeat dose tox studies- expected effects due to pharmacological action. Antigenicity: Non significantly inmunogenic in monkeys -Genotoxicity, carcinogenicity, reproduction toxicity : not conducted
27 Nivolumab -Preclinical toxicity conducted in monkey- similarities in tissue binding profiles between cynomolgus monkeys and humans indicate that is an appropriate animal model.rat and rabbit- no-binding -Specific safety pharmacology studies were limited to a single-dose CVS safety study in Cynomolgus monkeys. Supported by ICH guidelines S6(R1), S7A, and S9.
28 Nivolumab -Toxicology: Repeat toxicity studies-1 and 3-month iv in monkeys.well tolerated Changes in immune cell parameters were observed, demonstrating that nivolumab elicited pharmacological responses in healthy monkeys. -Genotoxicity, carcinogenicity, fertility and early embryonic development not conducted-supported according to Guidelines Embryofoetal toxicity in eppnd study -No dedicated local tolerance studies conducted -No general nonspecific immunostimulatory or autoimmune-related toxicities were observed. -ADAs were detected in 67% monkeys receiving monthly doses of nivolumab
29 -No submitted studies for genotoxicity, carcinogenicity as well as fertility and early embryonic development. Pembrolizumab -The pharmacology of pembrolizumab was evaluated in Cynomolgus monkey as the similarities in binding affinities with human PD-1 were observed in in vitro experiments compared to mouse, rat and dog, where no binding was observed. -Stand-alone studies evaluating safety pharmacology of pembrolizumab were not submitted (assessed in tox studies) -No non-clinical dedicated pharmacodynamic drug-drug interactions studies with pembrolizumab were submitted. -The toxicity of pembrolizumab was evaluated in a 1-month and a 6-month repeat-dose study in cynomolgus monkeys. Well tolerated and the NOAEL in both studies was the highest dose tested.
30 Elotuzumab -Elotuzumab only recognizes human SLAMF7 protein. -Because elotuzumab does not recognize non-human forms of SLAMF7 protein, in vivo safety data from animal studies are irrelevant. In the same line, no carcinogenicity data are available for elotuzumab in animals, nor were fertility and embryo foetal toxicity studies performed. Non clinical safety information primarily consists of limited in vitro human cell/tissue studies where no safety findings were identified. -Clinical trials data were therefore an important source of information to support the safety in patients.
31 CONCLUSIONS - Relevant animal model- poor predictive toxicology-limited data - Immunogenicity non-predictive data - Immune-related adverse events (iraes) assessment nonpredictive data - New complex combinations limited data Risk mitigation strategies should be adopted for CT
33 CONCLUSIONS CLASSIC CYTOTOXIC THERAPY TOXICOLOGY DATA PHARMACOLOGICAL DATA Careful monitoring of patients adverse effects
34 CONCLUSIONS IMMUNOTHERAPY PRODUCTS PHARMACOLOGY DATA TOXICOLOGY DATA Careful monitoring of patients immune function
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
European Medicines Agency July 2008 CPMP/ICH/286/95 ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Step 3 NOTE FOR
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals U.S. Department of Health and Human Services Food and Drug
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
M3(R2) Implementation Working Group M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions & Answers
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
ews in onclinical Evaluation of Anticancer Pharmaceuticals: ICH guideline S9 and beyond Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-aturwissenschaftlichen
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
18 March 2010 EMEA/CHMP/BMWP/301636/2008 Corr.* Committee for Medicinal Products for Human Use (CHMP) Guideline on non-clinical and clinical development of similar biological medicinal products containing
European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS
Challenges in early clinical development of biologics Peter Lloyd March 2011 Acknowledgements: Jennifer Sims, Phil Lowe, Sebastian Spindeldreher, Andrew Warren Protein therapeutics biologics Current generation
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
Product Development Services for Global Registration of Drugs & Biologics 16-17 th April 2014 Contact: firstname.lastname@example.org CONTENT OF PRESENTATION» History» Company Profile» Current Services» Proof-of-Concept:
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
1 2 3 03 June May 2013 EMEA/CHMP/BMWP/42832/2005 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing biotechnology-derived
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
30 May 2012 EMA/CHMP/BMWP/403543/2010 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing monoclonal antibodies non-clinical and clinical
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
dixa a data infrastructure for chemical safety Jos Kleinjans Dept of Toxicogenomics Maastricht University Current protocol for chemical safety testing Short Term Tests for Genetic Toxicity Bacterial Reverse
European Medicines Agency Evaluation of Medicines for Human Use London, 28 June 2006 Doc. Ref. EMEA/CHMP/BWP/398498/2005-corr CHMP/BWP DRAFT GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL
Guideline for the Preparation or Manipulation of Monoclonal Antibodies (MABs) and related compounds such as Fusion Proteins, used in the Treatment of Cancer Date Approved by Network Governance July 2012
Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
Classification of Hazardous Drugs by NIOSH Thomas H. Connor, PhD Research Biologist National Institute for Occupational Safety and Health NIOSH Goals Protect workers from exposure to hazardous drugs Provide
Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary
Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification
18 December 2014 EMEA/CHMP/BMWP/42832/2005 Rev1 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based
Quality and Safety Evaluation of Gene Therapy Products in Japan Review Mechanism for Gene Therapy in Japan The review mechanism for gene therapy in Japan was partially amended to simplify the necessary
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
P0LICYI013 PREGNANCY AND SEXUAL HEALTH POLICY Manual: Policies Document ID: PI013 Date Created: Jun 08 Section: Investigator No. Pages: 7 Review Date: Aug 15 Future Review Date: Aug 17 PURPOSE To describe
Targeted Chemotherapy Delivery Platform Igor Sherman, PhD President & CEO Richard Potts, Chairman 2014 Change in Age Adjusted US Death Rates by Cause Almost unchanged over 50 years Source: U.S. National
Biosimilars Demystified Thijs J. Giezen, PhD, PharmD, MSc Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem Member Biosimilar Working Party, European Medicines Agency I attend this conference
Antibody Drug Nomenclature: What is INN a Name? WHO Has Been Changing Them? Paul J. Carter Staff Scientist and Senior Director Antibody Engineering Genentech Inc. -umab -zumab -ximab -omab Antibody Engineering
HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial
Corporate Presentation November 2013 NASDAQ: GALT www.galectintherapeutics.com Forward Looking Statements This presentation contains, in addition to historical information, statements that look forward
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT email@example.com National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy
Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely
24 May 2012 EMA/CHMP/BMWP/86289/2010 Committee for Medicinal Products for Human Use (CHMP) Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Draft agreed
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer